PE20080259A1 - Compuestos y metodos para modular fxr - Google Patents

Compuestos y metodos para modular fxr

Info

Publication number
PE20080259A1
PE20080259A1 PE2007000629A PE2007000629A PE20080259A1 PE 20080259 A1 PE20080259 A1 PE 20080259A1 PE 2007000629 A PE2007000629 A PE 2007000629A PE 2007000629 A PE2007000629 A PE 2007000629A PE 20080259 A1 PE20080259 A1 PE 20080259A1
Authority
PE
Peru
Prior art keywords
alkyl
methyl
haloalkyl
compounds
ilmetoxy
Prior art date
Application number
PE2007000629A
Other languages
English (en)
Inventor
Michael Gregory Bell
Robert Anthony Doti
Michael James Genin
Peter Ambrose Lander
Tianwei Ma
Nathan Bryan Mantlo
Jason Matthew Ochoada
Lindsay Scott Stelzer
Ryan Edward Stites
Alan M Warshawsky
Matthew Scott Dowling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20080259A1 publication Critical patent/PE20080259A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE p 0-1; X1 y X2 SON C, N CON LA CONDICION DE QUE AMBOS X1 y X2 NO SON N; R1 y R2 SON H, ALQUILO C1-C3, HALOALQUILO C1-C3, ENTRE OTROS; R4b ES H, ALQUILO C1-C3, HALOALQUILO C1-C3, ENTRE OTROS; R5 y R5a SON CADA UNO H, ALQUILO C1-C3; R6 ES H, ALQUILO C1-C3, HALOALQUILO C1-C3, ENTRE OTROS; L1 ES ENLACE, ETINILO, ALQUILO C1-C3, ENTRE OTROS; Ar1 ES INDOLILO, BENZOTIENILO, NAFTILO, ENTRE OTROS; R7 ES -COOH, -ALQUILO C1-C3COOH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 4-[({4-[3-(2,6-DICLOROFENIL)-5-TRIFLUOROMETIL-3H-[1,2,3]TRIAZOL-4-ILMETOXI]-2-METILOFENIL}-METILAMINO)-METILO]-2-METIL-BENZOICO; ACIDO 3-[({4-[3-(2,6-DICLORO-FENIL)-5-ISOPROPIL-3H-[1,2,3]TRIAZOL-4-ILMETOXI]-2-METIL-FENIL}-METIL-AMINO)-METILO]-BENZOICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON AGONISTAS SELECTIVOS PARA EL FXR (RECEPTOR FARMESOIDE X) UTILES EN EL TRATAMIENTO DE DISLIPIDEMIA, ATEROESCLEROSIS, DIABETES Y ENFERMEDADES RELACIONADAS
PE2007000629A 2006-05-24 2007-05-22 Compuestos y metodos para modular fxr PE20080259A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80810406P 2006-05-24 2006-05-24
US87000106P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
PE20080259A1 true PE20080259A1 (es) 2008-04-10

Family

ID=38626336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000629A PE20080259A1 (es) 2006-05-24 2007-05-22 Compuestos y metodos para modular fxr

Country Status (16)

Country Link
US (1) US8106077B2 (es)
EP (1) EP2029558B1 (es)
JP (1) JP5225984B2 (es)
AR (1) AR061101A1 (es)
AT (1) ATE460403T1 (es)
AU (1) AU2007267692B2 (es)
BR (1) BRPI0711875A2 (es)
CA (1) CA2651373A1 (es)
CL (1) CL2007001451A1 (es)
DE (1) DE602007005256D1 (es)
EA (1) EA014720B1 (es)
ES (1) ES2340221T3 (es)
MX (1) MX2008014959A (es)
PE (1) PE20080259A1 (es)
TW (1) TW200812982A (es)
WO (1) WO2007140174A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1894928A1 (en) * 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101945848A (zh) 2007-12-20 2011-01-12 英维沃医药有限公司 四取代的苯
WO2009102761A1 (en) 2008-02-12 2009-08-20 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type i inhibitors
EP2128158A1 (en) * 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
CA2735886A1 (en) 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag Indazole or 4,5,6,7-tetrahydro-indazole derivatives
EP2289883A1 (en) * 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8252826B2 (en) 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EA201390476A1 (ru) 2010-09-28 2013-08-30 Бристол-Майерс Сквибб Компани Новые пиперазиновые аналоги с замещенными гетероарильными группами в качестве противовирусных средств широкого применения против гриппа
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
WO2012062623A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Triazole derivatives as ligands for gaba receptors
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
IL253437A0 (en) * 2011-07-13 2017-09-28 Gilead Sciences Inc New compounds modulate fxr (nr1h4) activity and bind
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
JP6223443B2 (ja) * 2012-06-26 2017-11-01 サニオナ・エイピイエス フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用
JP6366721B2 (ja) 2013-09-11 2018-08-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物
CN106660967A (zh) 2014-01-24 2017-05-10 西纳福克斯股份有限公司 (杂)芳基1，3‑偶极化合物与(杂)环炔的环加成方法
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MA41094A (fr) * 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
US11311557B2 (en) 2015-02-06 2022-04-26 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
PE20180034A1 (es) 2015-04-07 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas
SG11201810600WA (en) 2016-06-13 2018-12-28 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018153933A1 (en) 2017-02-21 2018-08-30 Genfit Combination of a ppar agonist with a fxr agonist
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
JP2020515564A (ja) 2017-03-30 2020-05-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物
PE20191792A1 (es) * 2017-04-12 2019-12-24 Il Dong Pharma Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
US11370785B2 (en) 2017-11-01 2022-06-28 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid X receptor modulators
AU2018360575A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
EP3704106B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
CN113302190A (zh) 2019-01-15 2021-08-24 吉利德科学公司 Fxr(nr1h4)调节化合物
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
BR112021024109A2 (pt) 2019-05-30 2022-03-22 Intercept Pharmaceuticals Inc Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
MX2022000742A (es) 2019-07-18 2022-02-14 Enyo Pharma Metodo para disminuir los efectos adversos del interferon.
CN110878052B (zh) * 2019-12-11 2021-05-07 山东大学 一种含有fxr激动剂的化合物及其制备方法和应用
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
EP4126858A1 (en) 2020-03-26 2023-02-08 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
DE60131967D1 (de) * 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2004048349A1 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
AU2004311909A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as PPAR modulators for the treatment of diabetes

Also Published As

Publication number Publication date
WO2007140174A3 (en) 2008-03-20
EP2029558A2 (en) 2009-03-04
JP2009538333A (ja) 2009-11-05
ATE460403T1 (de) 2010-03-15
CL2007001451A1 (es) 2008-01-11
EP2029558B1 (en) 2010-03-10
EA200870569A1 (ru) 2009-06-30
BRPI0711875A2 (pt) 2012-01-10
DE602007005256D1 (de) 2010-04-22
US20090093524A1 (en) 2009-04-09
EA014720B1 (ru) 2011-02-28
ES2340221T3 (es) 2010-05-31
TW200812982A (en) 2008-03-16
WO2007140174A2 (en) 2007-12-06
JP5225984B2 (ja) 2013-07-03
AU2007267692A1 (en) 2007-12-06
US8106077B2 (en) 2012-01-31
MX2008014959A (es) 2008-12-09
CA2651373A1 (en) 2007-12-06
AR061101A1 (es) 2008-08-06
AU2007267692B2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
PE20080259A1 (es) Compuestos y metodos para modular fxr
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20110905A1 (es) Arilpirrolidinas pesticidas
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20080362A1 (es) Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20110672A1 (es) 4-fenil-1-h-pirazoles insecticidas
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20050444A1 (es) Compuestos de piridina como inhibidores de la peptidasa
PE20090641A1 (es) Amidas heterociclicas
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
PE20010987A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20051147A1 (es) Compuestos de heteroaril y fenilsulfamoilo sustituidos
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20091425A1 (es) Derivados de aminotiazol
AR094588A2 (es) Proceso de obtención de un compuesto derivado de benzimidazol y composición farmacéutica
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
CO5550431A2 (es) Cristales que incluyen una sal de acido malico de n-[2 (dietilamino)etil]-5-[(5-fluoro-2oxo-3h-indol-3-ilideno) metil]-2,4-dimetil-1h-pirrol-3-carboxamida, proceso para su preparacion y composiciones de esta
PE20010749A1 (es) Inhibidores de tirosin-cinasas
PE20030547A1 (es) Derivados de imidazol para el tratamiento de la obesidad
PE20060240A1 (es) Derivados de pirimidina para tratar el crecimiento celular anomalo
PE20080858A1 (es) Compuestos de n-aril pirazol y composiciones que los contienen
PE20060554A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina como inhibidores de la fosfotirosina fosfatasa 1b y procedimientos para su preparacion
PE20071034A1 (es) Compuestos heterociclicos como inhibidores de cetp

Legal Events

Date Code Title Description
FD Application declared void or lapsed